SCHEMBL10102676

SCHEMBL10102676

CNCCCNC(=O)C(O)CCc1cc2cc(C(F)(F)F)ccc2nc1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.40
NAMPT P43490 1/20 0.38
PTGFR P43088 6/20 0.38
TACR1 P25103 3/20 0.37
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
TACR3 P29371 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
DHFR P00374 2/20 0.35
NTRK1 P04629 1/20 0.35
SCD O00767 1/20 0.35
CTSK P43235 1/20 0.34
KCNH2 Q12809 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13004928 0.83 DHODH (0.46) DHODHPTGFRDHFRNTRK1KDM4E
SCHEMBL10102678 0.76 AKT1 (0.37) PTGFRMTNR1AMTNR1BCTSKKCNH2
SCHEMBL3383001 0.73 DHODH (0.45) DHODHDHFRCTSKKCNH2KDM4E
SCHEMBL10102671 0.73 DHODH (0.46) DHODHDHFRKCNH2KDM4E
SCHEMBL10107731 0.73 DHODH (0.39) DHODHDHFR
SCHEMBL13005203 0.70 AKT1 (0.36) DHODHPTGFRDHFRKDM4EALDH1A1
SCHEMBL13005210 0.67 AKT1 (0.39) DHODHPTGFRSCDKDM4EALDH1A1
SCHEMBL13005263 0.66 DHFR (0.40) DHODHNAMPTTRPV1DHFRNTRK1
SCHEMBL10102667 0.66 PSMB5 (0.43) PTGFRKDM4EALDH1A1GAAHPGD
SCHEMBL28170261 0.66 PDE10A (0.63) DHODHPTGFRDHFRKCNH2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B DHODH 961/4885NAMPT 4283/4885PTGFR 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.